ArticleScientific reports2026
Anti-aging potential of Limosilactobacillus fermentum F-B9-1-2 extracellular vesicles in D-galactose-induced cellular and organ senescence.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Aging is characterized by progressive loss of skin elasticity, reduced motor performance, cognitive decline, and deterioration of multiple organ systems. Developing effective anti-aging interventions is crucial for mitigating these degenerative changes. This study aimed to investigate the protective effects of Lactobacillus-derived extracellular vesicles derived from Limosilactobacillus fermentum strain F-B9-1-2 (LDEVs) D-galactose (D-gal)-induced mice, using nicotinamide mononucleotide (NMN) as a positive control. LDEVs were isolated and characterized by electron microscopy and nanoparticle tracking analysis. In vitro, LDEVs significantly enhanced the viability of human umbilical vein endothelial cells (HUVECs) and markedly attenuated D-galactose–induced cellular senescence, as evidenced by reduced senescence-associated β-galactosidase staining. In vivo, behavioral assessments showed that LDEVs administration improved spontaneous locomotor activity and learning–memory performance in D-gal–induced mice. Biochemical analyses showed that LDEVs modulated tissue-specific functional and aging-related markers in the skin, brain, and liver. RT-qPCR analysis indicated downregulation of p16, p19, and p21 expression in the liver and brain, as well as IL-6 expression in the skin. Histological examinations of hippocampal and cutaneous tissues further supported the protective role of LDEVs. Collectively, these findings indicate that LDEVs are associated with attenuation of D-gal–induced aging-like phenotypes in mice, accompanied by reduced cellular senescence, inflammation, and oxidative stress. This study provides preliminary evidence supporting the potential of probiotic-derived extracellular vesicles as candidate anti-aging agents, warranting further validation in naturally aged models and mechanistic investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.